Table 6.
Common adverse events in induction and consolidation phase including hepatotoxicity according to CTCAE grading.
| Adverse Event N(%) | Induction phase | Consolidation phase | ||
|---|---|---|---|---|
| Fever | 25 (31.6%) | 33 (41.8%) | ||
| Infection | 24 (30.4%) | 29 (36.7) | ||
| Thrombosis | 14 (17.7%) | 3 (3.8%) | ||
| Bleeding | 9 (11.4%) | 1 (1.3%) | ||
| Hyperglycemia | 34 (43%) | 6 (7.6%) | ||
| Allergic reaction | 24 (30.4%) | 24 (30.4%) | ||
| Pancreatitis | 10 (12.6%) | 2 (2.5%) | ||
| Adverse event | Grade1 | Grade2 | Grade3 | Grade4 |
| Induction | ||||
| Transaminases N(%) | 35 (44,3%) | 12 (15%) | 18(22.8%) | 4(5.1%) |
| Bilirubin N(%) | 20 (25%) | 21 (26%) | 9(11.4%) | 2(2.5%) |
| Consolidation | ||||
| Transaminases N(%) | 35(44.3%) | 20 (25.3%) | 17 (21.5%) | 0 |
| Bilirubin N(%) | 21(26.6%) | 20(25.3%) | 4 (5.1%) | 1 (1.3%) |